Our tested plant-derived compounds downregulated key ETS transcription members including ETS2, ETS1, ETV1, ETV4, and ETV5. Testing of these compounds in Ewing’s sarcoma and prostate cancer is worthwhile as these cancers are characteristic of aberrant ETS genetic lesions. This evidence concerns the gene ETS2 and prostate cancer.